TGFB1 and non-small cell lung carcinoma: In a previous report on cilengitide combined with the EGFR inhibitor gefitinib, we confirmed their cytotoxicity in CPAE cells and a synergistic effect on NSCLC cell viability and TGF-β1–induced EMT phenotype changes [36].